870281-86-0

Basic information

• Product Name: (S)-2-(1-aMinopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
• Synonyms: (S)-2-(1-aMinopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one;2-[(1S)-1-Aminopropyl]-5-fluoro-3-phenyl-4(3H)-quinazolinone;Idelalisib INT;CAL-101 (N-1) Intermediate;(S)-2-(1-((9H-purin-6-yl-2,8-d2)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one;IdelalisibIntermediates 1
• CAS NO: 870281-86-0
• Molecular Formula: C₁₇H₁₆FN₃O
• Molecular Weight: 297.3268432
• Product Categories: intermediate;intermediates
• Mol File: 870281-86-0.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 455.3±55.0 °C(Predicted)
• Appearance: /
• Density: 1.27±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 8.23±0.29(Predicted)
• CAS DataBase Reference: (S)-2-(1-aMinopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(1-aMinopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one(870281-86-0)
• EPA Substance Registry System: (S)-2-(1-aMinopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one(870281-86-0)

Safety Data

• Hazardous Substances Data: 870281-86-0(Hazardous Substances Data)

Usage

General Description

The chemical compound "(S)-2-(1-aMinopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one" is a quinazolinone derivative with a fluorine atom and a phenyl group attached to the quinazolinone ring. Its molecular structure includes an (S)-2-(1-aminopropyl) side chain, which contains a primary amine group. (S)-2-(1-aMinopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one has potential pharmacological properties due to its quinazolinone scaffold, which is known for its various biological activities, including anticancer, antimicrobial, and anti-inflammatory effects. The functional groups present in the molecule offer opportunities for further modification and development of novel drug candidates for the treatment of various diseases.

Upstream product

• 870281-85-9 (S)-(1-(5-fluoro-4-carbonyl-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamic acid tert-butyl ester 
• 870281-83-7 2-fluoro-6-nitro-N-phenyl-benzamide 
• 870281-84-8 (S)-[1-(2-fluoro-6-nitro-benzoy)phenylaminocarbonyl]propyl carbamic acid tert-butyl ester 
• 1417456-04-2 2-amino-6-fluoro-N-phenyl-benzamide 
• 62-53-3 aniline 
• 385-02-4 6-fluoro-2-nitrobenzoic acid 
• 78755-94-9 5-fluoro-2H-benzo[d][1,3]-oxazine-2,4(1H)-dione 
• 434-76-4 2-amino-6-fluorobenzoic acid 

Downstream Products

• 870281-82-6 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-3,4-dihydroquinazolin-4-one 

Relevant articles and documents

Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies

Phosphatidylinositol 3-kinases (PI3Ks) mediate intracellular signal transduction. Aberrant PI3K signaling is associated with oncogenesis and disease progression in solid tumors and hematologic malignancies. Idelalisib (1), a first-in-class PI3Kδ inhibitor for the treatment of hematologic malignancies, was developed, but its sales were limited by black box warnings due to unexpected adverse effects. Therefore, to overcome these adverse events, various quinazolinone derivatives were synthesized and evaluated in vitro based on their inhibitory activity against the PI3K enzyme and the viability of cell lines such as MOLT and SUDHL. Among them, 6f (IC50 = 0.39 nM) and 6m (IC50 = 0.09 nM) showed excellent enzyme activity, and 6m displayed an approximately four-fold higher selectivity for PI3Kγ/δ compared with Idelalisib (1). Furthermore, in vivo PK experiments with 6f and 6m revealed that 6f (AUClast = 81.04 h*ng/mL, Cmax = 18.34 ng/mL, Tmax = 0.5 h, t1/2 = 10.2 h in 1 mpk dose) had improved PK compared with 1. Finally, further experiments will be conducted with 6f selected as a candidate, and the potential for it to be developed as a treatment with good efficacy for hematologic malignancies will be determined.

PROCESS FOR PREPARING IDELALISIB

The present invention relates to an improved process of preparation of idelalisib using a solid form of intermediate of formula (2); characterized by XRPD pattern having 2θ values 5.5°, 10.9°, 14.3°, 16.9° (±0.2) the process comprising steps a. Reacting o

PROCESS FOR THE PREPARATION OF AMORPHOUS IDELALISIB

The present invention relates to a process for the preparation of stable and 5 pure amorphous form of Idelalisib. Further, the present process is simple, more economical, cost effective and efficient method of manufacturing that is suitable for industrial